Download
s00296-020-04752-9.pdf 1,17MB
WeightNameValue
1000 Titel
  • Glucocorticoid maintenance therapy and severe infectious complications in ANCA-associated vasculitis: a retrospective analysis
1000 Autor/in
  1. Speer, Claudius |
  2. Altenmüller-Walther, Christine |
  3. Splitthoff, Jan |
  4. Nusshag, Christian |
  5. Kälble, Florian |
  6. Reichel, Paula |
  7. Morath, Christian |
  8. Zeier, Martin |
  9. Bergner, Raoul |
  10. Schaier, Matthias |
1000 Erscheinungsjahr 2020
1000 Publikationstyp
  1. Artikel |
1000 Online veröffentlicht
  • 2020-11-22
1000 Erschienen in
1000 Quellenangabe
  • 41(2):431-438
1000 Copyrightjahr
  • 2020
1000 Lizenz
1000 Verlagsversion
  • https://doi.org/10.1007/s00296-020-04752-9 |
  • https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7835159/ |
1000 Publikationsstatus
1000 Begutachtungsstatus
1000 Sprache der Publikation
1000 Abstract/Summary
  • To study the impact of glucocorticoid maintenance dose and treatment duration on outcomes in patients with AAV (ANCA-associated vasculitis) with emphasis on infectious complications. A total of 130 AAV patients from two German vasculitis centers diagnosed between August 2004 and January 2019 treated with cyclophosphamide and glucocorticoids for induction therapy and glucocorticoids for maintenance therapy were retrospectively enrolled. We investigated the influence of glucocorticoid maintenance therapy on patient survival, time to relapse, kidney function, infectious complications and irreversible physical damage. The patients were divided into the following groups: patients treated according to the predefined reduction scheme (< 7.5 mg) or patients treated with glucocorticoids ≥ 7.5 mg after 6 months. Compared to patients receiving < 7.5 mg glucocorticoids after 6 months, patients receiving [Formula: see text] 7.5 mg had an increased rate of infectious episodes per patient (1.7 vs. 0.6; p < 0.001), including urinary tract infection (p = 0.007), pneumonia (p = 0.003), opportunistic pneumonia (p = 0.022) and sepsis (p = 0.008). Especially pneumonia during the first 24 months after disease onset [hazard ratio, 3.0 (95% CI 1.5 - 6.1)] led to more deaths from infection (p = 0.034). Glucocorticoid maintenance therapy after 6 months had no impact on relapse rate or patient survival and decline in kidney function was comparable. Glucocorticoid maintenance therapy with [Formula: see text] 7.5 mg after 6 months is associated with more severe infectious complications leading to an increased frequency of deaths from infection. Glucocorticoid maintenance therapy has no effect on time to relapse or patient survival and should therefore be critically revised throughout the aftercare of AAV patients.
1000 Sacherschließung
lokal Dose-Response Relationship, Drug [MeSH]
lokal Immunosuppressive Agents/administration
lokal Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis/drug therapy [MeSH]
lokal Adverse effects
lokal Humans [MeSH]
lokal Observational Research
lokal Pneumonia/chemically induced [MeSH]
lokal Retrospective Studies [MeSH]
lokal Cyclophosphamide/adverse effects [MeSH]
lokal Cyclophosphamide/administration
lokal Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis/mortality [MeSH]
lokal Recurrence [MeSH]
lokal Glucocorticoids
lokal Disease-Free Survival [MeSH]
lokal Drug Therapy, Combination/adverse effects [MeSH]
lokal Remission Induction [MeSH]
lokal Sepsis/chemically induced [MeSH]
lokal Glucocorticoids/administration
lokal Glucocorticoids/adverse effects [MeSH]
lokal Immunosuppressive Agents/adverse effects [MeSH]
lokal ANCA-associated vasculitis
1000 Liste der Beteiligten
  1. https://orcid.org/0000-0002-3668-5916|https://frl.publisso.de/adhoc/uri/QWx0ZW5tw7xsbGVyLVdhbHRoZXIsIENocmlzdGluZQ==|https://frl.publisso.de/adhoc/uri/U3BsaXR0aG9mZiwgSmFu|https://frl.publisso.de/adhoc/uri/TnVzc2hhZywgQ2hyaXN0aWFu|https://orcid.org/0000-0002-6321-7341|https://frl.publisso.de/adhoc/uri/UmVpY2hlbCwgUGF1bGE=|https://orcid.org/0000-0001-5838-9301|https://frl.publisso.de/adhoc/uri/WmVpZXIsIE1hcnRpbg==|https://orcid.org/0000-0002-7965-1273|https://orcid.org/0000-0003-1040-1150
1000 Hinweis
  • DeepGreen-ID: f5145ab05d2842bc8f593528a2be365b ; metadata provieded by: DeepGreen (https://www.oa-deepgreen.de/api/v1/), LIVIVO search scope life sciences (http://z3950.zbmed.de:6210/livivo), Crossref Unified Resource API (https://api.crossref.org/swagger-ui/index.html), to.science.api (https://frl.publisso.de/), ZDB JSON-API (beta) (https://zeitschriftendatenbank.de/api/), lobid - Dateninfrastruktur für Bibliotheken (https://lobid.org/resources/search)
1000 Label
1000 Dateien
1000 Objektart article
1000 Beschrieben durch
1000 @id frl:6469218.rdf
1000 Erstellt am 2023-11-17T21:09:33.630+0100
1000 Erstellt von 322
1000 beschreibt frl:6469218
1000 Zuletzt bearbeitet Fri Dec 01 09:26:56 CET 2023
1000 Objekt bearb. Fri Dec 01 09:26:56 CET 2023
1000 Vgl. frl:6469218
1000 Oai Id
  1. oai:frl.publisso.de:frl:6469218 |
1000 Sichtbarkeit Metadaten public
1000 Sichtbarkeit Daten public
1000 Gegenstand von

View source